



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/043,813	09/29/1998	MICHAEL T. KELLY	85010340301	7331

500 7590 07/30/2003

SEED INTELLECTUAL PROPERTY LAW GROUP PLLC
701 FIFTH AVE
SUITE 6300
SEATTLE, WA 98104-7092

[REDACTED] EXAMINER

GUPTA, ANISH

ART UNIT	PAPER NUMBER
1654	33

DATE MAILED: 07/30/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/043,813	KELLY ET AL.
	Examiner	Art Unit
	Anish Gupta	1654

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 02 May 2003.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-6 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-6 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
 If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ .
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ .	6) <input type="checkbox"/> Other: _____ .

DETAILED ACTION

1. The request filed on 5-2-03 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 16 is acceptable and a CPA has been established. An action on the CPA follows.

Claim Objections

2. Claims 1-4 are objected to because of the following informalities: Applicants are requested to place the corresponding SEQ. ID. NO. next to claimed sequence as required by 37 CFR 1.821(d). Appropriate correction is required.

Double Patenting

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321© may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claims 1-4 and 5-6 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 54 of U.S. Patent No. 5,962,407. Although the conflicting claims are not identical, they are not patentably distinct from each other because .

In previous responses, Applicants argues that the claims 54 of the US patent is drawn to a pharmaceutical formulation, whereas the claims of the instant application are drawn to compounds. “[T]he pharmaceutical formulations are directed to composition that include various derivatives of isolated compounds, not the compounds themselves.” Applicants argue that one could, for instance, prepare a derivative of a compound according to the synthetic methodology disclosed in, for example, Example A4(col. 14, lines 26 to col. 16, line 39) of the issued patent, and then formulate that derivative into a pharmaceutical composition, while never generating or handling the ‘isolated compounds’ *per se*. ”

Applicant's arguments have been fully considered but they are not persuasive.


As stated in the previous office, claim 54 recites “A pharmaceutical composition comprising a *compound*, derivative or salt of any claims 1-4, 9-12, 25-31, or 34-40 and a pharmaceutically acceptable carrier.” Therefore the claim clearly envisions the isolation of the compound to achieve the pharmaceutical formulation and further distinguishes between the compound and its derivatives or salts since the claims recites all three. Furthermore, Applicants seem to be limiting the scope of the US Patent to a specific method for obtaining the pharmaceutical formulation. However, the claims do not recite such a limitation. They are open to any method of making such a pharmaceutical formulation. Note that in the US Patent,

pharmaceutical formulations can be made by "Formula (A or B) in admixture or otherwise in association with one or more carriers." (See col. 10, lines 46-49). Thus this method clearly envisions handling the "isolated compounds". Thus, there are method of making pharmaceutical formulations that would utilize "isolated compounds" per se.

Further, Note that claim 55 also recites the use of "a therapeutically effective amount of a compound" for the treatment of a patient afflicted with a bacterial function. Therefore claim 55 also envisions the use of a compound, in addition to the derivatives and salts to practice the method.

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anish Gupta whose telephone number is (703) 308-4001. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback , can normally be reached on (703)306-3220. The fax phone number of this group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.



Anish Gupta 1/20/03

A handwritten signature of "Anish Gupta" is written over a large, stylized, open circle. To the right of the signature, the date "1/20/03" is handwritten vertically.